By the time most rural patients see a neurologist, they have already traveled hundreds of miles to get there, and in many cases, they arrive too late. The newest wave of Alzheimer's advances, blood biomarker tests, earlier detection windows, disease-modifying treatments, is unfolding almost entirely inside major academic medical centers. For patients outside those corridors, that progress might as well be happening on another continent. Jontel Pierce MD, a neurologist building prevention-focused practices with rural communities in mind, believes the field has been asking the wrong question. The issue is not just treatment access. It is whether the patients most likely to be overlooked ever get evaluated at all.
Pierce's approach flips the conventional model. Where standard neurology practice addresses Alzheimer's at clinical onset, when symptoms have already declared themselves, Pierce recommends targeted lifestyle modifications based on blood biomarkers and genetic risk profiles years before any symptom presents. The goal, as Pierce describes it, is to prevent the disease outright or at minimum delay when it arrives. That kind of proactive framework requires catching patients early, which is precisely where rural communities face the steepest barriers.
The underrepresentation of rural patients in neurology clinical trials, Pierce argues, comes down to two compounding problems. Distance is the first. As Pierce puts it,
"most people in rural communities have to travel hundreds of miles to see a neurologist. Many times they are unaware that they may benefit from a neurological evaluation."
The second problem is informational. Even when rural patients are within reach of a trial site, they often have no frame of reference for what clinical trials are or how they might qualify. Awareness is not a minor obstacle here. It is, in many cases, the whole wall. This is why Pierce has oriented a significant part of the practice around improving access to specialists and clinical trials specifically for rural populations, using AI tools for patient monitoring and trial matching designed with those health systems in mind rather than retrofitted from big-city infrastructure.
The conversation around cognitive decline also extends beyond Alzheimer's pathology alone. Pierce draws a direct line between traumatic brain injury and long-term neurological risk, noting that when someone suffers a TBI, the neuronal system is disrupted in ways that produce immediate deficits in memory, mood, and balance. Most of the time those symptoms resolve within days to weeks. But as Pierce notes, a small percentage of patients go on to experience persistent symptoms for months or years, and for that group, interventional post-concussion management is where the long-term focus needs to land. In rural communities, where sports injuries and occupational hazards are common and specialist follow-up is scarce, that population may be going unmonitored and unmatched to the trials most relevant to their history.
The tools exist, or are being built. The patients are there. What remains unresolved is whether the systems connecting those two things will be designed with rural realities in mind from the start, or whether rural patients will spend another generation waiting for advances that were never quite built for them.

